



Revolutionizing healthcare
with Exosomes

September 2024



EVerZom, pioneering exosome therapeutics



**Founded
in 2019**

>10

years of research

€7m

already raised to
develop the
exosome platform



**Exosomes,
the next therapeutic
revolution**

Breakthrough scientific
revolution

8,800

research papers (2022),
21% CAGR

Strong dynamics in
funding and **licensing deals**



**A proprietary
exosome
therapeutic platform**

Cell **sourcing and exosome
generation, loading and
formulation**

5 patents

protecting the platform

Robust manufacturing
and scale-up capacities



€12m
for a Series A

Phase I/II on Crohn and
Hidradenitis suppurativa
fistula

Development of
regenerative programs **in
liver**

Partnerships with pharmas
based on the platform



Unique selling proposition in the exosome space

Focus on stem cell exosomes for their **natural high intrinsic therapeutic efficacy**



Optimized formulation with hydrogel to enable optimal efficacy



Manufacturing technology and know-how enabling **100x higher yield** low manufacturing cost and only 10L to enter the clinics



Versatile pipeline in digestive tissue healing, dermatology and hepatology



Proprietary programs addressing unsatisfied medical needs



Key indications like Crohn, and Hidradenitis suppurativa fistula **to demonstrate the efficacy of the platform** (clear readout, local administration, orphan, short clinical trials, low number of patients)



What are exosomes?

nature

FedEx for your cells:
this biological delivery
service could treat
disease

Researchers want to know
why cells produce tiny
packages called vesicles –
and whether these bundles
could be used for therapy.

Exosomes are ~150nm nanoparticles released by cells enabling **cell to cell communication** thanks to RNA, lipids & proteins with **intrinsic regenerative properties and delivery capabilities**




Allow information transfer
in **any type of cell**



Ability to **cross biological membranes**
like the blood-brain barrier



Intrinsic qualities recapitulating
the **mother cell properties**




Capacity to be engineered
with a **biomolecular cargo**

In the body, there are 10 times more exosomes than cells

Exosome promise

Strong research,
a skyrocketing number
of **publications** and
an increasing number of
clinical trials are structuring
the future of exosomes



8,800 papers
in 2022, very high
research intensity

>25
clinical trials
with exosomes

Exosome therapeutic biotechs are highly
attractive for investors and pharmas

MAIN FUNDRAISINGS



Stem cell exosomes
ARDS/Covid-19
Fistula

\$100M
Phase III



Stem cell exosomes
Aesthetic medicine

\$50M
Phase I/II

MAIN LICENSING DEALS in the past 3 years



Red blood cell exosomes
Gene therapy for
rare disease

\$800M
Undisclosed upfront
Discovery/Preclinical



HEK cell exosomes
siRNA for
neuroal diseases

\$1.1B
\$20M upfront
Discovery/Preclinical

More than **200**
companies working
on exosomes

EverZom development vision

EverZom aims to develop numerous **proprietary and co-developped treatments** in 3 key therapeutic areas



Digestive wound healing

Key targeted indication:
Crohn disease fistula

E.g. anastomosis healing (cancer & bariatric), fibrostenosis, post surgical adhesion.



Dermatology

Key targeted indication:
Verneuil disease fistula

E.g. atopic dermatitis, diabetic ulcer, radiation fibrosis



Liver regeneration

Key targeted indication:
Acute on chronic liver failure (ACLF)

E.g. Acute liver failure acute alcoholic hepatitis, acute decompensation of cirrhosis...

Building the next-generation therapeutics

EverZom therapeutic platform is **unique** and **validated** by several academic, financial and industrial partners

01



Exosome
innovation
platform

02



Proprietary &
co-developed
therapeutic
programs

île de France



bpifrance

Innov'up Leader PIA

Business Angels

European
Innovation
Council



French
Bioproduction

Inserm

Université
Paris Cité


ASSISTANCE
PUBLIQUE HÔPITAUX
DE PARIS



+more than **20**
industrials partners

A holistic innovation platform


EverZom platform is built on three blocks **from the cell source to the formulated exosome drug**
Protected by 5 patents



From adipose derived mesenchymal stem cells to exosomes for patients.




Mother cell
modification



Exosome
generation




Formulation




EverZom proprietary therapeutic pipeline

Everzom develops its proprietary pipeline of naïve exosomes **in regenerative therapies**,
large market indications with high unmet medical needs





EverZom solution: EVerGel

Stem cell exosomes delivered via a **thermoresponsive gel** to facilitate controlled release and enhance retention



EverGel has demonstrated **successful in vitro and in vivo POC results on fistula***



EverGel accelerate healing, reduce inflammation and fibrosis

* >100 animals injected with Exosomes / 250 in total (80 rats – 20 pigs) - 8 models tested (3 pig models / 5 rat models)

EVerZom strategy

Significant value inflection point

Series A

€12M equity

€8M non-dilutive & tax credit

Seed

€0.8M equity

€6.2M non-dilutive
including EIC accelerator

June
2020

October
2024

Milestones achieved

- Efficacy validation *in vivo*
- Scale up to 10L bioreactor
- GMP manufacturing (Q1-2024)

End of 2027
Potential
exit/strategic
transaction

Milestones to be achieved

- Non clinical toxicity and safety
- Clinical safety
- Clinical efficacy POC for Hidradenitis suppurativa and Crohn fistula (phase I/IIa)
- Pipeline and platform extension
- 1 major deal with a pharma

A complementary multidisciplinary team & boards

Jeanne VOLATRON
CEO & co-founder

PhD in Nanotechnologies
Centrale Entrepreneur
HEC Entrepreneur
Deeptech Founders



Nicolas ROUSSEAU
COO & co-founder

Biomedical engineer Centrale
Supelec School
HEC Entrepreneur
Deeptech Founders



+18
Team members

Max PIFFOUX
Scientific Advisor & co-founder

MD - fellow (oncology)
PhD in biotechnology
MSc biostatistics
Hospices Civils de Lyon
INSERM



STRATEGIC BOARD



Michel Finance

Ex-CEO at Affluent
Medical, Theradiag,
Carmat,
Board President



Julie Rachline

CEO LallianSe,
Brintale



Laurent Bracco

Business Angel



Jean-François Brepson

CEO Pathoquest



Thibaut De Tessières

Business Angel

CLINICAL BOARD



Gabriel Rahmi

Shareholder
Gastroenterologist
HEGP Hospital
Board President



Antoine Monsel

ICU doctor
Hepatologist
La Pitié Salpêtrière
Hospital



Antoine Mariani

Surgeon – Department
of gastrointestinal
cancer surgery
HEGP Hospital

SCIENTIFIC BOARD



Amanda Brun, PharmD

Co-founder
Researcher at CNRS &
Exosome expert
Board President



Florence Gazeau
Co-founder

CNRS Research
director
Exosome expert



Pierre Launay, PhD

CEO of Inatherys



Eric Quemeneur, PhD

CSO of Transgene

Why invest?

EVERZOM

